Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia
Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia
Sponsor: Sanofi Pasteur, a Sanofi Company
A PHASE3 clinical study on Dengue and Dengue Fever, this trial is completed. The trial is conducted by Sanofi Pasteur, a Sanofi Company and has accumulated 11 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Jan 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Nov 2018 — Jan 2019 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Jun 2018 — Nov 2018 [monthly]
Unknown Status PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Feb 2017 — Apr 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Jun 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sanofi Pasteur, a Sanofi Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ban Pong, Thailand , Bandung, Indonesia , Cebu City, Philippines , Denpasar, Indonesia , Jakarta, Indonesia , Kuala Lumpur, Malaysia , Long Xuyen, Vietnam , Mỹ Tho, Vietnam , Nai Muang, Thailand , Photharam, Thailand and 2 more locations